El artículo con el que oficialmente cambia de nombre el "Síndrome de ovario poliquístico (SOP)" a "Síndrome ovárico metabólico poliendocrino", en The Lancet (2026).
Se une a la lista:
🔵 Diabetes Insípida -> Deficiencia de Arginina Vasopresina (AVP-D) o Resistencia a la Arginina Vasopresina (AVP-R)
🔵 Viruela del mono (Monkeypox)-> Mpox
🔵 Cirrosis Biliar Primaria -> Colangitis Biliar Primaria (CBP)
🔵 Hígado graso -> Enfermedad Hepática Esteatótica Asociada a Disfunción Metabólica (MASLD)
🔵 Síndrome de ovario poliquístico (SOP) -> Síndrome ovárico metabólico poliendocrino
https://t.co/3O93s10lns
Individuals on long-term oral #glucocorticoid treatment display an estimated prevalence of #osteoporosis or #fractures as high as 30–50%, rendering glucocorticoid therapy the most common cause of secondary and iatrogenic osteoporosis https://t.co/ZmMFAOJSc4
#BoneHealth
Although the treatment of checkpoint inhibitor-associated autoimmune diabetes (CIADM) broadly mirrors that of type 1 #diabetes, several key differences distinguish the two conditions https://t.co/0NHWlK2EDY
#T1D#CIADM
Since its first description by Thomas Addison in 1855, dramatic advancements have been made in management of Addison's disease, transforming it from a predominantly lethal disease to a manageable condition with, in most cases, expected long-term survival https://t.co/BHCdqdlX4g .